Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Belka

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 1, 2020
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective studyN-S Schmidt-Hegemann, S G C Kroeze, C Henkenberens, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trialS Peters, E Felip, U Dafni, et al.
Clinical and Translational Radiation Oncology|April 8, 2024
Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter <i>SMILE</i> phase II trialC A Fink, J Ristau, C Buchele, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology GroupT Eder, A K Hess, R Konschak, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 9, 2022
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)D Martin, T Schreckenbach, P Ziegler, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2016
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiationI Tinhofer, V Budach, M Saki, et al.
ESMO Open|November 29, 2021
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neckB Keam, J-P Machiels, H R Kim, et al.
World Journal of Urology|February 21, 2020
Correction to: The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrenceA Karl, A Buchner, C Tympner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitorsE S M van Aken, B Devnani, A Prelaj, et al.
World Journal of Urology|February 16, 2015
The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrenceA Karl, A Buchner, C Tympner, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
European Journal of Nuclear Medicine and Molecular Imaging|February 1, 2020
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective studyN-S Schmidt-Hegemann, S G C Kroeze, C Henkenberens, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trialS Peters, E Felip, U Dafni, et al.
Clinical and Translational Radiation Oncology|April 8, 2024
Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter <i>SMILE</i> phase II trialC A Fink, J Ristau, C Buchele, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology GroupT Eder, A K Hess, R Konschak, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 9, 2022
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)D Martin, T Schreckenbach, P Ziegler, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2016
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiationI Tinhofer, V Budach, M Saki, et al.
ESMO Open|November 29, 2021
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neckB Keam, J-P Machiels, H R Kim, et al.
World Journal of Urology|February 21, 2020
Correction to: The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrenceA Karl, A Buchner, C Tympner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitorsE S M van Aken, B Devnani, A Prelaj, et al.
World Journal of Urology|February 16, 2015
The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrenceA Karl, A Buchner, C Tympner, et al.
Pageof 12